<生产厂家价格>

盐酸普鲁卡因胺

盐酸普鲁卡因胺用途

盐酸普鲁卡因胺是一种抗心律失常药物,用于治疗心律失常。

盐酸普鲁卡因胺名称

[ CAS 号 ]:
614-39-1

[ 中文名 ]:
盐酸普鲁卡因胺

[ 英文名 ]:
ProcainaMide hydrochloride

[英文别名 ]:

Promide
MFCD00012998
Procainamide HCl
Procainamide hydrochloride
EINECS 210-381-7
Procainamide HCL USP

盐酸普鲁卡因胺生物活性

[ 描述 ]:

盐酸普鲁卡因胺是一种抗心律失常药物,用于治疗心律失常。

[ 相关类别 ]:

信号通路 >> 自噬 >> 自噬

研究领域 >> 其他

[参考文献]

[1]. Zamponi GW, et al. Dual actions of procainamide on batrachotoxin-activated sodium channels: open channel block and prevention of inactivation. Biophys J. 1993 Dec;65(6):2324-34.

[2]. http://en.wikipedia.org/wiki/Procainamid

[相关活性小分子]

盐酸普鲁卡因胺物理化学性质

[ 沸点 ]:
421.8ºCat 760 mmHg

[ 熔点 ]:
165-168 °C

[ 分子式 ]:
C₁₃H₂₂ClN₃O

[ 分子量 ]:
271.786

[ 闪点 ]:
208.9ºC

[ 精确质量 ]:
271.145142

[ PSA ]:
58.36000

[ LogP ]:
3.11450

[ 外观性状 ]:
白色至略黄色粉末

[ 储存条件 ]:
室温

[ 水溶解性 ]:
soluble

盐酸普鲁卡因胺MSDS

详细MSDS(安全技术说明书)

盐酸普鲁卡因胺毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: CV2295000

CHEMICAL NAME :: Benzamide, p-amino-N-(2-(diethylamino)ethyl)-, hydrochloride

CAS REGISTRY NUMBER :: 614-39-1

LAST UPDATED :: 199712

DATA ITEMS CITED :: 16

MOLECULAR FORMULA :: C13-H21-N3-O.Cl-H

MOLECULAR WEIGHT :: 271.83

WISWESSER LINE NOTATION :: ZR DVM2N2&2 &GH

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 857 mg/kg/60D-I

TOXIC EFFECTS :: Blood - agranulocytosis

REFERENCE :: AHJOA2 American Heart Journal. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1925- Volume(issue)/page/year: 105,1035,1983

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 200 mg/kg/4W-I

TOXIC EFFECTS :: Blood - thrombocytopenia

REFERENCE :: AIMDAP Archives of Internal Medicine. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1908- Volume(issue)/page/year: 145,700,1985

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 2786 mg/kg/56W-I

TOXIC EFFECTS :: Blood - leukopenia Musculoskeletal - joints

REFERENCE :: AJMEAZ American Journal of Medicine. (Technical Pub., 875 Third Ave., New York, NY 10022) V.1- 1946- Volume(issue)/page/year: 80,999,1986

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 10 mg/kg/6M-C

TOXIC EFFECTS :: Vascular - BP lowering not characterized in autonomic section

REFERENCE :: CPHADV Clinical Pharmacy. (American Soc. of Hospital Pharmacists, 4630 Montgomery Ave., Bethesda, MD 20814) V.1- 1982- Volume(issue)/page/year: 4,504,1985

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1509 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: TOVEFN Toksikologicheskii Vestnik. (18-20 Vadkovskii per. Moscow, 101479, Russia) History Unknown Volume(issue)/page/year: (2),28,1997

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 18,1127,1968

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 95 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 18,1127,1968

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 225 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold

REFERENCE :: JPPMAB Journal of Pharmacy and Pharmacology. (Pharmaceutical Soc. of Great Britain, 1 Lambeth High St., London SEI 7JN, UK) V.1- 1949- Volume(issue)/page/year: 14,253,1962

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1110 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 18,1127,1968

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 290 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: JPMSAE Journal of Pharmaceutical Sciences. (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037) V.50- 1961- Volume(issue)/page/year: 59,1405,1970

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 800 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: PSEBAA Proceedings of the Society for Experimental Biology and Medicine. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1903/04- Volume(issue)/page/year: 73,236,1950

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 94640 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,719,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 860 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 9,332,1954 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 2200 mg/kg/22D-I

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia Related to Chronic Data - death

REFERENCE :: TOVEFN Toksikologicheskii Vestnik. (18-20 Vadkovskii per. Moscow, 101479, Russia) History Unknown Volume(issue)/page/year: (2),28,1997 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X4522 No. of Facilities: 306 (estimated) No. of Industries: 2 No. of Occupations: 7 No. of Employees: 17913 (estimated) No. of Female Employees: 13936 (estimated)

盐酸普鲁卡因胺安全信息

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H302-H315-H319-H335

[ 警示性声明 ]:
P301 + P312 + P330-P305 + P351 + P338

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Gloves

[ 危害码 (欧洲) ]:
Xn:Harmful;

[ 风险声明 (欧洲) ]:
R22;R36/37/38

[ 安全声明 (欧洲) ]:
S26-S36-S37/39

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
3

[ RTECS号 ]:
CV2295000

[ 海关编码 ]:
2924299090

盐酸普鲁卡因胺上下游产品

盐酸普鲁卡因胺上游产品

盐酸普鲁卡因胺下游产品

盐酸普鲁卡因胺制备

对硝基苯甲酰氯与二乙氨基乙胺缩合，得到对硝基-N-（2-二乙氨基乙基）苯甲酰胺（硝基卡因胺），再经催化氢化生成普鲁卡因胺，然后用盐酸成盐即为本品。

盐酸普鲁卡因胺海关

[ 海关编码 ]: 2924299090

[ 中文概述 ]:
2924299090. 其他环酰胺（包括环氨基甲酸酯）（包括其衍生物以及他们的盐）. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:30.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 包装

[ Summary ]:
2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%

盐酸普鲁卡因胺文献

Chemical genetics reveals a complex functional ground state of neural stem cells.

Nat. Chem. Biol. 3(5) , 268-273, (2007)

The identification of self-renewing and multipotent neural stem cells (NSCs) in the mammalian brain holds promise for the treatment of neurological diseases and has yielded new insight into brain canc...

Phase II metabolism in human skin: skin explants show full coverage for glucuronidation, sulfation, N-acetylation, catechol methylation, and glutathione conjugation.

Drug Metab. Dispos. 43(1) , 126-39, (2014)

Although skin is the largest organ of the human body, cutaneous drug metabolism is often overlooked, and existing experimental models are insufficiently validated. This proof-of-concept study investig...

Thermal pretreatments of superficially porous silica particles for high-performance liquid chromatography: Surface control, structural characterization and chromatographic evaluation.

J. Chromatogr. A. 1419 , 45-57, (2015)

This study reports the impact of thermal pretreatment between 400 and 1100°C on superficially porous silica particles (e.g. core-shell, fused-core; here abbreviated as SPP silica). The different therm...

更多文献